Shu Ning

1.6k total citations
41 papers, 1.3k citations indexed

About

Shu Ning is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Shu Ning has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 15 papers in Pulmonary and Respiratory Medicine and 12 papers in Pharmacology. Recurrent topics in Shu Ning's work include Prostate Cancer Treatment and Research (14 papers), Pharmacogenetics and Drug Metabolism (12 papers) and PARP inhibition in cancer therapy (6 papers). Shu Ning is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Pharmacogenetics and Drug Metabolism (12 papers) and PARP inhibition in cancer therapy (6 papers). Shu Ning collaborates with scholars based in United States, China and Canada. Shu Ning's co-authors include Chung S. Yang, John F. Brady, Christopher Patten, Anthony Y.H. Lu, Paul E. Thomas, Mong-Heng Wang, Jun-Yan Hong, Mao‐Jung Lee, Carol B. Pantuck and Theresa J. Smith and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Oncogene.

In The Last Decade

Shu Ning

38 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shu Ning United States 19 630 478 265 219 209 41 1.3k
Ivan Gut Czechia 26 690 1.1× 763 1.6× 695 2.6× 431 2.0× 141 0.7× 63 2.0k
Shigeyuki Uno Japan 24 384 0.6× 678 1.4× 294 1.1× 484 2.2× 72 0.3× 43 1.8k
Parveen Abidi United States 17 428 0.7× 845 1.8× 183 0.7× 254 1.2× 220 1.1× 25 2.2k
Andrea Sapone Italy 24 305 0.5× 740 1.5× 429 1.6× 119 0.5× 155 0.7× 61 1.7k
Mark A. Tirmenstein United States 20 428 0.7× 547 1.1× 218 0.8× 138 0.6× 87 0.4× 39 1.5k
Lutz W. D. Weber Germany 15 1.0k 1.6× 480 1.0× 211 0.8× 305 1.4× 274 1.3× 31 2.2k
Craig B. Marcus United States 22 416 0.7× 542 1.1× 205 0.8× 221 1.0× 84 0.4× 51 1.4k
Ada Serroni United States 16 427 0.7× 711 1.5× 207 0.8× 83 0.4× 146 0.7× 23 1.6k
Richard M. Philpot United States 28 997 1.6× 815 1.7× 440 1.7× 409 1.9× 168 0.8× 54 2.2k
Gunilla Ekström Sweden 17 420 0.7× 463 1.0× 177 0.7× 76 0.3× 84 0.4× 30 1.5k

Countries citing papers authored by Shu Ning

Since Specialization
Citations

This map shows the geographic impact of Shu Ning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu Ning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu Ning more than expected).

Fields of papers citing papers by Shu Ning

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu Ning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu Ning. The network helps show where Shu Ning may publish in the future.

Co-authorship network of co-authors of Shu Ning

This figure shows the co-authorship network connecting the top 25 collaborators of Shu Ning. A scholar is included among the top collaborators of Shu Ning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu Ning. Shu Ning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ning, Shu, Wei Lou, Pui‐Kai Li, et al.. (2025). Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer. Cancers. 17(12). 1959–1959. 1 indexed citations
2.
Ma, Na, Bo Chen, Yin Huang, et al.. (2024). Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management. Critical Reviews in Oncology/Hematology. 207. 104604–104604. 3 indexed citations
3.
Chen, Bo, Pengfei Xu, Joy C. Yang, et al.. (2024). Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Oncogene. 43(30). 2325–2337. 3 indexed citations
4.
Ning, Shu, Wei Lou, Alan P. Lombard, et al.. (2024). PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells. Cancer Research Communications. 4(11). 2976–2985.
5.
Ning, Shu, Enming Xing, Wei Lou, et al.. (2024). LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy. Cancer Research. 84(21). 3617–3628. 4 indexed citations
6.
Ning, Shu, Cameron M. Armstrong, Leandro S. D’Abronzo, et al.. (2024). IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience. 27(2). 108984–108984. 6 indexed citations
7.
Ning, Shu, Cameron M. Armstrong, Wei Lou, et al.. (2023). Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer. Cancers. 15(21). 5273–5273. 3 indexed citations
8.
Xu, Pengfei, Joy C. Yang, Shu Ning, et al.. (2023). Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models. Pharmacological Research. 189. 106692–106692. 6 indexed citations
9.
Ning, Shu, Chengfei Liu, Wei Lou, et al.. (2022). Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Molecular Cancer Therapeutics. 21(10). 1594–1607. 16 indexed citations
10.
Lombard, Alan P., Cameron M. Armstrong, Leandro S. D’Abronzo, et al.. (2022). Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate Cancer. Molecular Cancer Therapeutics. 21(4). 677–685. 14 indexed citations
11.
Armstrong, Cameron M., Chengfei Liu, Liangren Liu, et al.. (2020). Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clinical Cancer Research. 26(22). 6064–6074. 17 indexed citations
12.
13.
Smith, Theresa J., et al.. (1992). Modulation of the levels of cytochromes P450 in rat liver and lung by dietary lipid. Biochemical Pharmacology. 43(12). 2535–2542. 41 indexed citations
14.
Ning, Shu, et al.. (1991). Regulation of Hepatic Microsomal Cytochrome P450IIE1 Level by Dietary Lipids and Carbohydrates in Rats. Journal of Nutrition. 121(7). 959–965. 93 indexed citations
15.
Brady, John F., Mong-Heng Wang, Jun-Yan Hong, et al.. (1991). Modulation of rat hepatic microsomal monooxygenase enzymes and cytotoxicity by diallyl sulfide. Toxicology and Applied Pharmacology. 108(2). 342–354. 111 indexed citations
16.
Park, Hee Sun, et al.. (1990). Effects of thiamine deficiency on hepatic cytochromes P450 and drug-metabolizing enzyme activities. Biochemical Pharmacology. 39(3). 519–525. 9 indexed citations
17.
Hong, Jun-Yan, et al.. (1990). Roles of pituitary hormones in the regulation of hepatic cytochrome P450IIE1 in rats and mice. Archives of Biochemistry and Biophysics. 281(1). 132–138. 23 indexed citations
18.
Brady, John F., et al.. (1990). Alteration of rat liver microsomal monooxygenase activities by gasoline treatment. Archives of Toxicology. 64(8). 677–679. 6 indexed citations
19.
Ishizaki, H., John F. Brady, Shu Ning, & Chung S. Yang. (1990). Effect of phenethyl isothiocyanate on microsomalN-nitrosodimethylamine metabolism and other monooxygenase activities. Xenobiotica. 20(3). 255–264. 66 indexed citations
20.
Brady, John F., Dechun Li, Hiroyuki Ishizaki, et al.. (1989). Induction of cytochromes P450IIE1 and P450IIB1 by secondary ketones and the role of P450IIE1 in chloroform metabolism. Toxicology and Applied Pharmacology. 100(2). 342–349. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ivan Gut Breakdown of academic impact, for papers by Shigeyuki Uno Breakdown of academic impact, for papers by Parveen Abidi Breakdown of academic impact, for papers by Andrea Sapone Breakdown of academic impact, for papers by Mark A. Tirmenstein Breakdown of academic impact, for papers by Lutz W. D. Weber Breakdown of academic impact, for papers by Craig B. Marcus Breakdown of academic impact, for papers by Ada Serroni Breakdown of academic impact, for papers by Richard M. Philpot Breakdown of academic impact, for papers by Gunilla Ekström
Rankless by CCL
2026